The LGC CDx Commercial team has been working on several high-impact projects over the past few months. Let's take a look!
In late September, members of the Commercial team attended AACC in Georgia, the first in-person AACC since 2018. Although the attendance wasn't what it had been pre-COVID-19, the team was able to connect with current customers, prospects, and partners. Overall, the event was considered a successful one! Pictured below in the LGC CDx booth are Eric Morreale from the Product Portfolio team and Jessica Tatem from the Marketing team.
Clinical Genomics recently welcomed two new Business Development Managers to the team: Darick Dayne and Abrahm Hinkel. Sales, Product Management, and R&D have worked together to create a strong pipeline for the rest of the fiscal year.
Technopath Clinical Diagnostics was slated to attend EuroMedLab in Munich, but the conference was postponed. In the video below, the TCD team introduces the Technopath value proposition to their European customers via multi-language narrative. Pretty impressive!
At API, a new molecular proficiency survey has been created to meet customer needs. Based on the changing dynamics involved with recommended COVID-19 testing, several diagnostic kit manufacturers have created multiplex assays targeting the most common upper respiratory viruses - SARS-CoV-2, Influenza A, Influenza B and RSV. Many API customers have adopted these multiplex assays as their first line of testing, to be able to rapidly and definitively identify the causative agents of disease. The new survey covers these targets and adoption has been very strong.
As the microbiology testing model shifts away from the growing of microorganisms for identification towards rapid molecular testing, API has been leading the response from PT providers, creating programs catered to these testing platforms. Diagnosis of urinary tract infections and antimicrobial resistance can now be performed by molecular multiplex analyzers. API has created the first PT program in the world for UTI multiplex testing, which launches 2022. The survey will challenge laboratories on identification and detection of resistance genes.
The Native Antigen Company’s team is working on bringing together the TNAC and KPL portfolios. KPL (formerly Kirkegaard & Perry Laboratories) was acquired by SeraCare in 2013 as a manufacturer of research and bulk reagents for IVDs and bioindustry. With the acquisition of TNAC in 2020, the two portfolios show natural synergies; TNAC’s portfolio largely comprises the critical reagents used in the development of immunoassays for the serological detection of pathogens, including viruses, bacteria and protozoa. Complementing this portfolio, the KPL range includes BacTrace® bacterial antigens and antibodies, as well as an extensive range of general accessory reagents needed to develop and run immunoassays.
Finally, we are thrilled to announce that TNAC's SARS-CoV-2 Neutralization Assay Development Kits have been recognized by The Scientist as a Top 10 Innovation of 2021. Every year The Scientist, a leading publication for life science professionals, announces a list of newly released tools, techniques, and technologies that it predicts will have the biggest impact on the life science industry. The Native Antigen Company’s assay development kits have been selected by an independent panel of expert judges as an innovative product that supports and speeds up biological discovery.
We are extremely thankful to The Scientist for awarding our Neutralization Assay Development Kits, and very proud of The Native Antigen Company's team for their combined efforts in developing these kits and their continued support of pandemic R&D.
